Bioxyne's (ASX:BXN) Breathe Life Sciences subsidiary dispatched its second shipment of Good Manufacturing Practice (GMP) MDMA capsules to the Victorian Government's Eastern Health department, according to a Wednesday filing with the Australian bourse.
The shipment will facilitate a clinical trial focused on MDMA-assisted psychotherapy for patients with co-occurring post-traumatic stress disorder and borderline personality disorder, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.